Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2023)

ArriVent BioPharma has reported Preferred Stock Liabilities over the past 1 years, most recently at $154.6 million for Q4 2023.

  • Quarterly results put Preferred Stock Liabilities at $154.6 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $154.6 million (changed N/A YoY), and the annual figure for FY2023 was $154.6 million, changed.
  • Preferred Stock Liabilities reached $154.6 million in Q4 2023 per AVBP's latest filing, roughly flat from $154.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $154.6 million in Q1 2023 and bottomed at $149.9 million in Q2 2023.